|
Chapter |
Session |
|
|
|
|
Chapter 1 Introduction and epidemiology |
C1-1. Intro and patient presentation Howard Takiff (Institut Pasteur - France) |
|
C1-2. History of TB Stephan Stenger (Ulm University - Germany) |
|
|
C1-3. TB Epidemiology Philippe Glaziou (WHO) |
|
|
C1-4. Effect of the COVID pandemic on TB epidemiology Nim Arinaminpathy (Imperial College - United Kingdom) |
|
|
C1-5. Immunology of TB introduction Steffen Stenger (Ulm University - Germany) |
|
|
C1-6. BCG Vaccin Brigitte Gicquel (Institut Pasteur - France) |
|
|
|
|
|
Chapter 2 Clinical context |
C2-1. Pulmonary TB Thomas Maitre (APHP - France) |
|
C2-2. Pediatric TB Christophe Delacourt (APHP - France) |
|
|
C2-3. Tuberculosis, HIV, Diabetes Véronique Joly (APHP - France) |
|
|
C2-4. Immune Reconstitution inflammatory Syndrome Howard Takiff (Institut Pasteur - France) |
|
|
C2-5. Subclinical TB Marcel Behr (Mc Gill University - Canada) |
|
|
|
|
|
Chapter 3 Diagnosis and Treatment |
C3-1. Radiological diagnosis of TB and contribution of Artificial Intelligence Guillaume Chassagnon (APHP - France) |
|
C3-2. Interferon gamma release assays for the diagnosis of TB Elisabeth Bouvet (APHP - France) |
|
|
C3-3. Microbiology for TB diagnosis Philippe Morand (APHP - France) |
|
|
C3-4. Nucleic acid tests for TB (NAATs) Philippe Morand (APHP - France) |
|
|
C3-5. Pitfalls in the molecular diagnosis of TB Nicolas Veziris (APHP - France) |
|
|
C3-6. Bacteriological basis of anti-tuberculosis treatment Nicolas Veziris (APHP - France) |
|
|
|
|
|
Chapter 4 Multi and Extensively Drug Resistant TB (MDR and XDR) |
C4-1. Diagnosing resistance beyond rifampicin resistance Philippe Morand (APHP - France) |
|
C4-2. Molecular techniques in lab flow Florence Morel (APHP - France) |
|
|
C4-3. Whole genome sequencing of M tuberculosis as an epidemiological marker Dick van Soolingen (National Institute for Public Health and the Environment, Bilthoven, Netherlands) |
|
|
C4-4. Whole genome sequencing of clinical Mycobacterium tuberculosis complex isolates Stefan Niemann (Research Center Borstel Leibniz Lung Center - Germany) |
|
|
C4-5. New drugs, new regimens Nicolas Veziris (APHP - France) |
|
|
|
|
|
Chapter 5 Phylogeny other TB Non Tuberculosis mycobacterium |
C5-1. The evolution of tuberculosis-causing mycobacteria Roland Brosch (Institut Pasteur - France) |
|
C5-2. M. africanum - a West African Cause of TB Bouke de Jong (Institute of Tropical Medicine Antwerp - Belgium) |
|
|
C5-3. M. bovis and One health Steve Gordon (University College Dublin - Ireland) |
|
|
|
|
|
Chapter 6 Immunology and vaccine |
C6-1. Innate immunity against TB Anca Dorhoi (Friedrich-Loeffler-Institut - Germany) |
|
C6-2. T cell response in TB Simone Joosten (LUMC - Netherland) |
|
|
C6-3. Host-directed therapy against TB Ludovic Tailleux (Institut Pasteur- France) |
|
|
C6-4. TB Vaccines Carlos Martin (University of Zaragoza - Spain) |
|
|
|
|
|
Optional clinical Chapter |
Option 1: Meningitis Howard Takiff (Institut Pasteur - France) |
|
Option 2: Pleural effusion Howard Takiff (Institut Pasteur - France) |
|
|
Option 3: Non Tuberculous Mycobacteria Jean-Louis Herrmann (APHP - France) |
|
|
Option 4: Non Tuberculous Mycobacteria treatments Jean-Louis Herrmann (APHP - France) |
|
|
Option 5: History of drug resistance in TB Howard Takiff (Institut Pasteur - France) |
|
|
Option 6: How TB drugs work? Howard Takiff (Institut Pasteur - France) |
|
